ASWB Clinical Practice Exam 2025 – Complete Study Resource

Clozaril, also known as clozapine, is an atypical antipsychotic that is particularly associated with an increased risk of agranulocytosis, which is a potentially life-threatening condition characterized by a dangerously low level of neutrophils (a type of white blood cell). Patients prescribed clozapine require regular monitoring of their white blood cell counts to detect any drops in neutrophil levels early on. The risk of agranulocytosis with clozapine makes it unique among antipsychotics, as other medications in the same class generally have a lower risk of this adverse effect.

In contrast, the other medications listed do not carry the same risk for agranulocytosis. Lexapro, an antidepressant, is not linked to this condition, and while lithium has its own array of side effects and requires monitoring, agranulocytosis is not commonly associated with it. Xanax, a benzodiazepine, also does not have a connection to agranulocytosis. Understanding these distinctions is vital for safe prescribing practices and for monitoring patients appropriately when they are on medications with these potential risks.